Beijing, China

Xiaofang Wang

This inventor holds 6 USPTO granted patents and 6 published patent applications and 7 EPO patents. Top assignees: Chinese Academy of Sciences, Newish Technology (Beijing) Co., Ltd.. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaofang Wang. Retrieved from https://idiyas.com/inventor/xiaofang-wang-44ojhki1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016-2024

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Xiaofang Wang

Introduction

Xiaofang Wang is a prominent inventor based in Beijing, China. He has made significant contributions to the field of medical technology, particularly in the development of innovative compositions for cancer treatment. With a total of 6 patents, his work focuses on enhancing the efficacy of cancer therapies.

Latest Patents

Xiaofang Wang's latest patents include groundbreaking inventions aimed at treating cancer. One notable patent is titled "Composition and use thereof in the manufacture of medicament for treating cancer." This invention provides a composition containing a compound of formula I or a pharmaceutically acceptable salt, dimer, or trimer thereof, along with a tyrosine kinase activity inhibitor. The method described in this patent aims to prevent and/or treat cancer by administering the composition to a subject in need. The combination of Sotagliflozin and a tyrosine kinase activity inhibitor is highlighted for its synergistic inhibitory effect on tumors, demonstrating significantly better efficacy than a single drug.

Another important patent is "Composition for treating cancer and use and medicament thereof." This invention relates to a composition that includes an SGLT1 inhibitor and a VEGFR2 inhibitor. The findings indicate that SGLT1 interacts with VEGFR2 to promote tumor development and progression. The composition combining a VEGFR2 targeting inhibitor and an SGLT1 inhibitor exhibits a synergistic anti-tumor effect, making it a promising option for cancer treatment.

Career Highlights

Xiaofang Wang has worked with esteemed organizations such as the Chinese Academy of Sciences and Newish Technology (Beijing) Co., Ltd. His experience in these institutions has allowed him to advance his research and contribute to significant innovations in cancer treatment.

Collaborations

Xiaofang has collaborated with notable colleagues, including Ming Gao and Dongyu Wang. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in the medical field.

Conclusion

Xiaofang Wang's contributions to cancer treatment through his innovative patents demonstrate his commitment to advancing medical technology. His work not only showcases his expertise but also holds the potential to significantly impact cancer therapy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…